Wound healing is a dynamic process that coordinates regeneration, proliferation, inflammation, and homeostasis. Late endothelial progenitor cells (LEPCs) are circulating blood stem cells that play a leading role in wound healing by supporting vascular repair. Following injury to the vasculature and tissue, hemostasis and the inflammatory reaction are initiated. Then, the injured endothelium provides signals for the mobilization and homing of circulating LEPCs. After homing, activated LEPCs initiate adhesion to vascular endothelial cells (ECs). In sequence, transendothelial migration into the sites of the wounded endothelium and differentiation into mature ECs proceed [1] [2] [3] [4] [5] . Throughout this process, LEPCs promote endothelial remodeling and wound healing by supplying neovasculature. Therefore, the therapeutic use of LEPCs holds promise for improving the outcome of wound healing and vascular regeneration.
Clinical interest has been focused on therapeutic angiogenesis by injecting ex vivo expanded LEPCs into patients. Various clinical studies have shown improved vascular outcomes in patients with ischemic and chronic wounds [2, 6] . However, one of the major challenges for this approach is that a low number of intravenously injected LEPCs reach the site of diseased target area due to their circulatory nature and low adhesion rate [7] . Therefore, improving LEPC delivery to injured tissue and enhancing the adhesion of LEPCs to the wounded area will greatly improve the use of LEPCs to improve therapeutic outcomes.
In this paper, we investigated a simple and effective way to improve the adhesion of LEPCs to the wounded endothelium using an inflammatory cytokine, interferon gamma (IFN-c). IFN-c is one of the most studied cytokines involved in various inflammatory reactions in response to wounding and infection [8] . IFN-c protects the body from infection and promotes healing following injury. Significantly more IFN-c is secreted from LEPCs when LEPCs are attached to fibrin, which implies its role in acute vascular injury [9] .
In our previous study, we performed transcriptome and proteome analyses of LEPCs and found that bone marrow stromal cell antigen 2 (BST2) was highly expressed in LEPCs and ECs [10] . BST2 is a type 2 transmembrane protein with unique topology that enables its homophilic tethering [11, 12] . Through its ability to tether itself and signal, BST2 is known as a host immune response molecule to viral infection as well as cell adhesion [13] . We investigated whether BST2 is involved in IFN-c effects on promoting LEPC adhesion to ECs and promoting angiogenesis. We hypothesized that injecting IFN-c-treated LEPCs can enhance the adhesion of LEPCs to wounded endothelium through specific BST2-BST2 homophilic interactions and thus promote vascularization.
We found that treating LEPCs with IFN-c resulted in enhanced adhesion of LEPCs to ECs, significantly increased neovascularization, and faster wound closure. Based on our findings, we suggest that IFN-c-stimulated LEPCs can improve current EPC-based cell therapy.
Materials and methods

Cell culture
Late endothelial progenitor cells (LEPCs) and human umbilical vein endothelial cells (HUVECs) were provided by Dr. SM Kwon at the College of Medicine, Pusan National University, as previously described [10] . LEPCs and HUVECs were maintained on dishes coated with 1% gelatin (Sigma, St. Louis, MO, USA) with EGM TM -2 medium at 37°C with 5% CO 2 in a humidified incubator. EGM TM -2 medium was changed every 48 h.
Reverse transcription-PCR and quantitative RT-PCR analysis
Total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. For each sample, 1 lg of total RNA was used for cDNA synthesis with random hexamers using an Omniscript RT kit (Qiagen, Hilden, Germany). PCR was performed in a thermocycler (Bio-Rad, Singapore) with GoTaq Ò DNA polymerase (Promega, Madison, WI, USA).
The relative expression of each mRNA was calculated by the comparative threshold cycle (C T ) method.
Construction of a BST2 extracellular domain protein expression vector
Full-length human BST2 cDNA was purchased from the Korea Humane Gene Bank, Medical Genomics Research Center (KRIBB, Korea). The extracellular domain (amino acids: 44-159) was generated as previously described [10] .
Scratch assay
Late endothelial progenitor cells ( 
Western blotting
Western blotting was performed as previously described [6] . Protein samples were resolved by SDS/PAGE and blotted onto PVDF membranes (Bio-Rad, Hercules, CA, USA), which were then labeled with the anti-BST2 primary antibody (1 : 1000 dilution) overnight at 4°C. The membranes were then incubated with secondary antibody for 1 h at RT, and antibody detection was performed using ECL Plus reagents (Thermo Fisher, Rockford, IL, USA).
Adhesion assay
Adhesion of LEPCs to HUVEC monolayers was examined as described with a modification [14] . HUVECs cultured in twelve-well plates were stimulated for 16 h with IFN-c (20 ngÁmL À1 ) in EGM-2 medium containing 0.5% FBS.
LEPCs were washed with PBS and resuspended in serumfree EBM-2 medium at 5 9 10 6 cellsÁmL À1 , and 100 lL isolated cells was added to IFN-c-treated HUVECs. BST2 extracellular domain protein was added 1 h before the addition of LEPCs. After a 4 h incubation at 37°C, nonadherent cells were removed by washing the cells twice with cold PBS. Adherent cells were lysed with 100 lL of 1% SDS solution for 1 h at 37°C, and the absorbance at 590 nm was determined using an automatic microplate reader.
Immunofluorescence staining
LEPCs were seeded on gelatin-coated (0.2%) glass coverslips and cultured in EGM-2 medium containing 0.5% FBS. After IFN-c (20 ngÁmL À1 ) stimulation for 20 h, the cells were fixed in 4% paraformaldehyde in PBS for 15 min at RT, washed three times for 5 min each with PBS containing 100 mM glycine, and permeabilized with 0.01% Triton X-100 in PBS for 1 min. Following blocking with 1% bovine serum albumin in PBS for 30 min at RT, the cells were incubated with rabbit anti-BST2 polyclonal antibody (1:500) in blocking solution overnight at RT and washed with PBS three times each for 10 min. Then, the cells were incubated with FITC-conjugated anti-rabbit IgG secondary antibody in blocking solution, and cells were imaged using a super resolution microscope (EVOS FL cell imaging, Life Technology).
Cell proliferation assay
Cell proliferation was measured via the CCK8 assay (Dojindo Molecular Technologies, Inc, Rockville, MD, USA) to determine relative cell growth after 12, 24, and 48 h. An aliquot of 10 lL of CCK8 solution was added to each 96well for 4 h of incubation at 37°C. Then, the absorbance at 450 nm was measured.
Tube formation assay
The Matrigel tube formation assay was performed as previously reported [6] . In brief, culture plates were coated with 70 lL of growth factor-reduced Matrigel TM (BD Biosciences, Bedford, MA, USA) per 48 wells. LEPCs were seeded on Matrigel-coated plates at a density of 2.5 9 10 4 cells per well in EGM-2 plus 2% FBS in the presence of 20 ngÁmL À1 VEGF (R&D), followed by incubation at 37°C for 24 h. Tube formation was examined by light microscopy 12 h later.
Flow cytometric analysis
Cells were treated with 0.05% trypsin-EDTA (Invitrogen, Grand Island, NY, USA) for 3 min in a 37°C incubator. The cells were dissociated by gentle pipetting and filtered through a 40-lm cell strainer. The dissociated cells were immediately resuspended at approximately 2 9 10 5 cells per mL in PBA (1% bovine serum albumin, 0.02% NaN 3 in PBS) and incubated with anti-BST2 antibody diluted with 3% BSA/PBS for 30 min at 4°C in the dark. After the cells were washed twice with PBA, they were incubated with PE-labeled secondary antibody diluted with 3% BSA/ PBS for 30 min in the dark. The cells were washed three times by centrifugation at 400 9 g for 5 min and resuspended in ice-cold PBS with 3% BSA. The cells were analyzed for antibody binding using FACSCalibur (BD Biosciences -Immunocytometry Systems and CELL QUEST software (BD Biosciences -Immunocytometry Systems).
Animals and tail wound healing assay
Animal experiment approval was acquired from the IACUC (SNU-170724-4) of the Seoul Nation University. Specific pathogen-free ICR mice (Koatech, Pyeongtaek, Korea) were purchased and bred in the animal facility. Ten-week-old female mice were used for this study. For tail wound healing assay, excisions were made on the dorsal surface of the tail, 0.3-0.7 cm distal to the body of the animal. Full-thickness wounds corresponding to the template area were created by using individual sterile #10 gauge scalpels (Becton Dickinson, Temse, Belgium). Bleeding was stopped by pressure application. To prevent infection, povidone-iodine (PVP-I, Povidone, Korea) was applied around the wound. Harvesting of tails for woundclosure analysis required anesthesia by intramuscular injection of a combination of anesthetics (80 mgÁkg À1 ketamine and 12 mgÁkg À1 xylazine) during the course of the study from day 0 (immediately after wounding) until 8 days after wounding. For cell treatment, 4.2x10 5 cells were diluted in 60 lL of PBS.
Cells were injected into the mouse tail vein with a 26-gauge syringe 3 days after surgery. The injection was performed over 15 min to slowly introduce the cells into vein. To detect the size of the wound, a ruler and ImageJ were used.
Statistical analyses
Data are presented as the means AE SD, and statistical comparisons between groups were performed using one-way ANOVA. * and ** indicate p < 0.05 and p < 0.01 compared to the control group, respectively.
Results
IFN-c selectively upregulates BST2 expression in LEPCs in a time-, dose-, and passage-dependent manner
Based on previous reports that IFN-c selectively upregulates BST2 expression in human umbilical cord bloodderived vascular cells (HUVEC), which are considered mature ECs (Fig. S1A) , we first examined BST2 expression in various human EC progenitor cells, including LEPCs, mesenchymal stem cells (MSCs), and adipose-derived stem cells (ADSCs). IFN-c selectively induced BST2 expression at very high levels in LEPCs (Fig. 1A) . FACs and immunofluorescence staining also showed that the expression of BST2 was, indeed, localized on the plasma membrane and in the cytoplasm of LEPCs (Fig. 1B,C) .
To assess the kinetics of BST2 upregulation in LEPCs, BST2 expression was detected after IFN-c stimulation by quantitative RT-PCR (qRT-PCR). BST2 was upregulated in a dose-dependent manner (Fig. 1D) , and its expression became evident after 4 h of stimulation and was induced up to 11.5-fold at 24 h with 50 ngÁmL À1 IFN-c (Fig. 1E) . BST2 was also upregulated in HUVECs in response to gradient doses of IFN-c (Fig. S1B ). In accordance with the real-time RT-PCR results, BST2 protein expression was also highly upregulated by 50 ngÁmL À1 IFN-c. Interestingly, we found that the BST2 level was upregulated in the later passages of LEPCs (Fig. 1F) . Additionally, later passages of LEPCs responded weakly and slowly to IFN-c stimulation, showing lower levels of BST2 than earlier passaged cells (Fig. 1G ). This result might be due to an internally activated inflammatory pathway in later stages of LEPCs.
IFN-c stimulated LEPCs showed enhanced adhesion to ECs
Next, we investigated whether IFN-c can enhance the adhesion of LEPCs to dishes and endothelium as in the in vitro conditions. We tested whether IFN-c can increase the binding of LEPCs to a HUVEC monolayer. First, we checked whether IFNc could improve the adhesion of LEPCs to a petri dish without any coating. LEPCs were treated with various concentrations of IFN-c (30, 50, 100, and 200 ngÁmL À1 ) for 12 h, trypsinized, and reseeded on a petri dish. After 3 h, the cell density was assessed.
There was no significant difference between the IFNc-treated and untreated groups ( Fig. 2A) . Then, to test the effect of IFN-c-on LEPC adhesion to ECs, LEPCs were treated with the same doses of IFN-c, trypsinized, and reseeded on a dish that was densely preseeded with a HUVEC monolayer. After 3 h, the cell adhesion of LEPCs to HUVECs was increased by approximately 18% in the group treated with 30 ngÁmL À1 IFN-c. There was an increasing trend of adhesion depending on the dose up to 50 ngÁmL À1 IFN-c (Fig. 2B ). Next, we tested whether IFN-ctreated LEPCs show enhanced adhesion to IFN-ctreated HUVECs. We performed the same cell adhesion experiment with an IFN-c-pretreated HUVEC monolayer. Adhesion was increased up to 26% when both cell types were treated with 30 ngÁmL À1 IFN-c (Fig. 2B ).
BST2 extracellular domain interrupts IFN-ctreated LEPC adhesion to HUVECs
One possible reason for this enhanced adhesion of LEPCs to HUVECs with IFN-c treatment is due to enhanced cell adhesion molecules, as suggested for T lymphocytes and ECs. We examined the expression of various cell adhesion molecules, including VCAM, ICAM, PECAM, and VE-cadherin, as well as the negative markers MMP2 and C-Kit. IFN-c upregulated VAM, ICAM, and PECAM 7-, 3-and 4-fold, respectively. IFN-c did not significantly change the levels of VE-cadherin, MMP2, and C-kit (Fig. 2C) . Since VCAM, ICAM, and PECAM are broadly distributed cell adhesion molecules found in a variety of cells and tissues, we focused our study on BST2 that is specifically expressed on LEPCs and HUVECs, inferring its importance in binding LEPCs to the endothelium.
To evaluate the role of BST2 in the specific association of LEPCs to HUVECs, we cloned the BST2 extracellular domain (ECD) protein (Fig. 3C) . It has been known that BST2 ECD was sufficient to evoke BST2 to BST2 homophilic adhesion. First, to examine whether BST2 ECD is sufficient to increase LEPC adhesion on a petri dish, the LEPC adhesion assay was performed on a petri dish precoated with BST2 ECD protein. Fragment crystallizable (Fc) protein was used as a negative control. Compared to the Fc-coated petri dish, LEPCs showed increased adhesion to the BST2 ECD-coated petri dish ( Figs 3A and S2A ). HUVECs were also increased by IFN-r on the BST2 ECD-coated petri dish (Fig. S2B) . Second, we examined whether treating BST2 ECD can effectively reduce the adhesion of IFN-c-treated LEPCs to HUVECs. The adhesion of LEPCs to HUVECs was reduced in the presence of 1 lg BST2 ECD, while treating the cells with the Fc protein did not change the adhesion of LEPCs (Fig. 3B) .
IFN-c enhanced the angiogenesis of LEPCs but did not affect proliferation and migration
Next, we examined whether IFN-c affects the angiogenic function of LEPCs. It has been reported that IFN-c enriched peripheral blood CD34 + progenitor cells ex vivo [15] . Additionally, IFN-c has been described as having both positive and negative effects on human EC proliferation [16, 17] . Although it is still debatable in human ECs, we found that IFN-c treatment results in no significant changes in LEPC proliferation (Fig. 4A) . Moreover, the scratch assay showed no changes after treating LEPCs with 50 ng, 100 ng, or 200 ng of IFN-c for 12 h, suggesting no changes in LEPC migration (Fig. 4B,C) . However, IFN-c treatment did affect the morphology and angiogenesis of LEPCs. LEPCs became thinner, and cells became lengthened by IFN-c. IFN-c treatment enhanced tube formation of LEPCs by up to 50% (Fig. 4D,E) . The qRT-PCR results showed an increase in the angiogenetic markers Flt-1, KDR, Angio1, vWF, and BST2 (Fig. 4F ). This result is also supported by a previous study in which IFN-c induced capillary growth of ECs [18] . This result suggests that IFN-c enhances angiogenesis in accordance with BST2 upregulation. LEPCs treated with IFN-c showed faster wound closure, which was inhibited by BST2 ECD Next, we investigated whether IFN-c-treated LEPCs have better efficacy in wound closure in vivo. Mice were subjected to tail excision resulting in a 0.3 9 0.5 cm wound and lateral tail vein injury. Three days after the excision, the mice were injected with PBS, LEPCs, LEPCs pretreated with IFN-c, or LEPCs pretreated with IFN-c + BST2 ECD proteins. On the following day, the mice were injected with cells again to make sure that cells were not leaking through the wounded lateral tail veins. Images were taken on day 4 and day 8 after excision (Fig. 5A) . Wound closure was analyzed by measuring the size of the wounded area. LEPCs treated with IFN-c showed greater wound closure compared to all groups (Fig. 5C,D) . LEPCs treated with IFN-c and BST2 ECD proteins showed reduced therapeutic efficacy. These results indicate that IFN-c enhances the wound healing effect of LEPCs, in part, through BST2-mediated cell interactions.
Discussion
In this study, we show that IFN-c-treated LEPCs enhanced BST2 expression that evoked BST2 to BST2 homophilic adhesion and thus increased wound healing (Fig. 6 ). Both LEPCs and HUVECs expressed BST2 at high levels (Fig. 1) . Our results indicate that LEPCs attach to ECs through BST2. LEPCs have advantages as therapeutic tools since they are circulating endothelial progenitor cells that express BST2, which is highly upregulated by IFN-c, although HUVECs have higher expression levels of BST2. It has been reported that LEPCs play a role in wound healing, with the greatest angiogenic potential [19, 20] . Clinical studies have also shown that LEPCs improve vascular outcomes in ischemic and chronic wound patients [2, 6] .
We found that BST2 levels were greater in the later passages of LEPCs than in earlier passages of LEPCs (Fig. 1F) . This finding could be evidence that the LEPCs become HUVEC-like cells [21] . IFN-c treatment of LEPCs also resulted in a thinner and longer cell morphology similar to HUVECs. In another report, circulating EPCs differentiated into ECs, and the EPC-derived ECs had immune privilege [22] . EPC-derived ECs showed dramatic endothelialization and induced only mild inflammatory responses. Together, these observations represent the potential of LEPC maturation to ECs by IFN-c and angiogenic therapeutic application.
BST2 ECD reduced the adhesion of LEPCs to HUVECs (Fig. 3B) . However, BST2 ECD did not completely block the effect of adhesion enhanced by IFN-c treatment. As other cell adhesion molecules also contribute to the adhesion between LEPCS and ECs, this incompleteness might be due to upregulated expression of other cell adhesion molecules. In fact, our data showed that IFN-c also increased the levels of the adhesion molecules VCAM, ICAM, and PECAM (Fig. 2C) .
Late endothelial progenitor cells treated with IFN-c showed greater outcomes in wound closure, even with xenogeneic cells (Fig. 5C,D) . Interestingly, injecting LEPCs alone did not show a significant therapeutic outcome compared with the PBS-injected group. This finding could be explained by low adhesion and fast passing of LEPCs injected into the tail vein ventral to the excision. That is, without the proper induction of cell adhesion molecules, including BST2, injected LEPCs did not adhere to the injured site due to fast blood flow and spread to the circulation system. Furthermore, LEPCs became EC-like cells and acquired privilege to immune responses by IFN-c. It has been reported that EPC-derived ECs have the ability to defend against allospecific cellular immune responses and humoral-mediated attacks. After transplantation with EPC-derived ECs, there was no rejection response, and the cells showed a therapeutic response because of less potency in the allogeneic stimulation of CD4+ T cells than aortic ECs [22] . Thus, our data indicate that the increased wound-closure effect was contributed by increased cell adhesion and immune privileges of the LEPCs after IFN-c treatment.
In conclusion, LEPCs treated with IFN-c showed superior therapeutic effects on wound closure. IFN-c enhanced the tube formation of LEPCs and adhesion to ECs mediated partially by the BST2 to BST2 interaction. Our findings provide evidence that LEPC-based therapy with the cell adhesion aspect of BST2 could be useful for vascular regeneration and wound healing.
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